The opioid epidemic both arises from and perpetuates a global crisis in pain treatment: How can we effectively treat pain while reducing the impact of addiction on individuals and society? Is ketamine the answer? 

In this episode, Dr. Jeffrey Becker, the CSO of Bexson Biomedical discusses their novel insulin pump-inspired delivery system for ketamine, ketamine’s application to chronic pain, and what inspired him to explore the clinical applications of psychedelics.

“Dr. Becker has over 20 years of research and clinical experience in NMDA-receptor pharmacology and clinical use. He was one of the first MDs in U.S. administering and documenting ketamine for depression in the clinic, and is a world recognized speaker and expert in the clinical use of ketamine. His expertise led to development of an effective nutraceutical product addressing NMDA-receptor abnormalities. He received his B.S. from UC Berkeley and M.D from UCLA. He maintains a clinical practice focused in Functional Psychiatry and novel treatment approaches to mental health challenges.” – bexsonbiomedical.com

Further reading:

Bexson Biomedical’s patent application:

https://patents.justia.com/patent/10973780

Ketamine in the pain clinic:

Peri-operative ketamine reduces post-operative opioid requirements.

A review of impact of ketamine on pain perception and one’s relationship towards pain.

A meta-analysis of clinical studies investigating the efficacy of ketamine for chronic pain.